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Angiotensin administration stimulates renal 11b-hydroxy-
steroid dehydrogenase activity in healthy men.
Background. We examined whether acute administration of
angiotensin modulates the activity of 11b-hydroxysteroid dehy-
drogenase (11bHSD), the intracellular enzyme catalyzing the
interconversion between the hormonally active cortisol and in-
active cortisone.
Methods. Twenty-one male healthy subjects were examined
after 1 week of a low- and high-salt diet (50 and 200 mmol/
day, respectively). Separate infusions of angiotensin I (Ang I)
and II (Ang II) were administered, both at rates of 4 and 8 ng/
kg/min. The ratios of tetrahydrocortisol + allotetrahydrocorti-
sol/tetrahydrocortisone (THF + allo-THF/THE) and of free
cortisol/free cortisone (UFF/UFE) in urine were measured
as indices of overall 11bHSD set point and activity of renal
11bHSD type 2, respectively. Glomerular filtration rate (GFR)
was measured by constant infusion of 125I-iothalamate.
Results. Ang I and Ang II infusion dose-dependently in-
creased mean arterial blood pressure (MAP) and plasma aldos-
terone, and decreased plasma renin activity (PRA) and GFR
at both diets. Ang I and Ang II infusion resulted in a dose-
dependent decrease in the excretion of UFF, UFE, and of the
UFF/UFE ratio at both diets, without changing the urinary
(THF + allo-THF)/THE ratio. Salt restriction did not affect
these 11bHSD variables, but was accompanied by a decrease in
UFF and UFE excretion.
Conclusion. This study suggests that acute angiotensin ad-
ministration stimulates the activity of 11bHSD type 2 in human
kidney. Angiotensin might therefore exert a dual effect on the
mineralocorticoid receptor (i.e., an indirect agonistic effect by
increasing aldosterone availability and a direct or indirect an-
tagonistic effect by stimulation of renal 11bHSD type 2 activity).
The renin-angiotensin-aldosterone system (RAAS) is
of key importance in the regulation of blood pressure
and sodium homeostasis. RAAS activation results in
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angiotensin II–mediated vasoconstriction, as well as in
direct and indirect stimulation of sodium retention in
the kidney by enhancing adrenal aldosterone secretion.
Activation of the renal mineralocorticoid receptor is
not uniquely restricted to aldosterone, as this recep-
tor demonstrates similar affinity to cortisol in vitro [1].
However, stimulation of the mineralocorticoid receptor
by cortisol in vivo is prevented by the intracellular en-
zyme 11bHSD type 2, which catalyzes the conversion
from the hormonally active cortisol to inactive cortisone
[2]. Thus, 11b-hydroxysteroid dehydrogenase (11bHSD)
type 2 acts as a gatekeeper by protecting the mineralocor-
ticoid receptor from inappropriate stimulation by corti-
sol. In addition, in vitro experiments have demonstrated
that dehydrocorticosterone (i.e., the equivalent of cor-
tisone in rodents) can by itself antagonize aldosterone-
mediated stimulation of the mineralocorticoid receptor
[3, 4]. The other isozyme present in humans, designated
11bHSD type 1, activates cortisone to cortisol in vivo [2].
11bHSD type 1 is widely distributed, whereas 11bHSD
type 2 is mainly expressed in mineralocorticoid target
organs like kidney, colon, and salivary glands [5, 6]. No-
tably, 11bHSD type 1 is virtually absent in human kidney
[7, 8].
In vitro experiments have suggested that the activity
of 11bHSD type 2 is inhibited by angiotensin II (Ang II)
[9, 10]. If extrapolated to in vivo conditions, these obser-
vations would imply that angiotensin can stimulate the
mineralocorticoid receptor both by releasing aldosterone
and by increasing cortisol availability in the kidney. On
the other hand, it has been demonstrated that Ang II
infusion stimulates 11bHSD type 2 activity in rats, pos-
sibly limiting the angiotensin-mediated activation of the
mineralocorticoid receptor [11]. Thus far, the effect of an-
giotensin administration on 11bHSD activity in humans
is unknown. In view of the aldosterone-lowering effect
of RAAS inhibitors such as angiotensin-converting en-
zyme (ACE) inhibitors and Ang II receptor blockers, it
is of relevance to know whether in vivo modulation of
angiotensin levels in humans is accompanied by changes
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in renal 11bHSD activity that might affect the level of
mineralocorticoid receptor activation.
Therefore, the aim of the present study was to examine
whether angiotensin infusion modulates the activity of
renal 11bHSD in healthy subjects. Subjects were studied
during a low- and high-sodium intake in order to assess
the effect of angiotensin infusion during different back-
ground levels of endogenous RAAS activity. Moreover,
glomerular filtration rate (GFR) was accurately mea-
sured to adjust for angiotensin-mediated changes in renal
function.
METHODS
Subjects and protocol
Twenty-one healthy Caucasian males were studied.
The study was approved by the local medical ethics com-
mittee, and written informed consent was obtained from
all participants. All subjects were normotensive, defined
as blood pressure <140/85 mm Hg. None of the subjects
used medications. The study design has been described in
detail previously and some of the subjects presented here
also participated in another study evaluating the interac-
tion between ACE insertion/deletion (I/D) genotype and
angiotensin response on blood pressure and renal hemo-
dynamics [12]. In brief, each participant was studied on
two separate occasions, after having used in randomized
order a low (50 mmol/day) and liberal (200 mmol/day;
further referred to as ‘high’) sodium diet for 1 week, with
a daily intake of 100 mmol potassium. The two diet pe-
riods were separated by at least 1 week. Glycyrrhizin-
containing products were prohibited during the study. On
day 7, 24-hour urine was collected for analysis and each
participant visited our research unit on day 8 at 8 hours
after an overnight fast. Blood samples were drawn at
8 hours and hourly thereafter from 10 hours to 18 hours.
Blood samples obtained at 12 hours were taken as base-
line before angiotensin infusion. Subjects remained in
semirecumbent position during the experimental day.
Urine samples were collected hourly from 10 hours un-
til 18 hours, and the mean values of the urine collected
from 10 hours to 12 hours was taken as baseline. Body
mass index (BMI) was calculated as weight divided by
height squared. Blood pressure was measured with an
automated device (Dinamap) (GE Medical Systems, Mil-
waukee, WI, USA) and the mean of the values recorded
between 10 hours and 12 hours was used as baseline. GFR
was measured by constant infusion of 125I-iothalamate
[13]. Angiotensin I (Ang I) and Ang II (Clinalfa AG,
Laufeifingen, Switzerland) were infused from 12 hours
to 14 hours and from 16 hours and 18 hours, respec-
tively, with a wash-out period between 14 hours and
16 hours. Both substances were infused at two different
rates of 4 and 8 ng/kg/min during the first and second
hour, respectively.
Laboratory measurements
Serum and urine electrolytes were determined
on a Mega Multi-Test analyzer (Merck, Darmstadt,
Germany). Plasma rennin activity (PRA) and aldos-
terone were assayed by radioimmunoassay (RIA).
Urinary-free cortisol (UFF) and free cortisone (UFE)
were measured by an in-house RIA after differential ex-
traction with organic solvents and affinity chromatogra-
phy [14]. The lower limit of detection for UFF and UFE
of the RIA was at 2 and 5 nmol/L, respectively. The cross-
reactivity of the UFF assay was 2.5% for cortisone, 1.7%
for corticosterone, and 9.5% for 11-desoxycortisol. For
the UFE assay, these percentages were 1.0%, <0.1%, and
0.7%, respectively. The intra- and interassay coefficients
of variation were 8% and 13% for the UFF assay, 9%
and 15% for the UFE assay. The ratio of UFF to UFE
was used as an index of 11bHSD type 2 activity in vivo
[15–17]. Urinary steroid metabolites were determined
by gas chromatography [18]. The intra- and interassay
coefficients of variation were 6.0 and 14.5% for
tetrahydrocortisol (THF), 6.0% and 23.0% for al-
lotetrahydrocortisol (allo-THF), 5.1% and 12.3% for
tetrahydrocortisone (THE), respectively. The overall set
point of 11bHSD activity in vivo was estimated as the
urinary ratio of THF + allo-THF/THE [2].
Statistical analysis
Data are presented as mean ± SD. UFF and UFE ex-
cretion rates determined on the actual experimental day
were corrected for the GFR of the corresponding urine
collection period. Changes during Ang I infusion were
compared to baseline and washout measurements, while
changes during Ang II infusion were compared to val-
ues of the preceding washout period as a second base-
line. Within group changes in variables were evaluated
by the Friedman two-way analysis of variance (ANOVA).
Between group differences in variables were compared
by the Mann-Whitney U test. Bivariate relationships be-
tween parameters were evaluated by Spearman’s rank
correlation analysis. Statistical significance was defined
as a two-sided P value < 0.05.
RESULTS
Mean age was 23 ± 2 years and mean BMI was
22.8 ± 2.7 kg/m2 in the 21 participants. Adherence to
the prescribed diets was adequate, as illustrated by the
24-hour urinary sodium excretion of 44 ± 31 mmol and
255 ± 68 mmol during low- and high-salt intake, respec-
tively (P < 0.001). After salt restriction, there was a small
decrease in body weight from 79 ± 11 kg to 78 ± 11 kg
(P < 0.05). Serum concentrations of sodium and potas-
sium at baseline were not different after salt restriction
and did not change significantly during Ang I or Ang II
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Table 1. Effect of angiotensin I (Ang I) and angiotensin II (Ang II) infusion on blood pressure, renal function, plasma renin activity (PRA), and
aldosterone during low- and high-salt diet
Ang I Ang I Ang II Ang II
Baseline (4 ng/kg/min) (8 ng/kg/min) Washout (4 ng/kg/min) (8 ng/kg/min)
Low-salt
MAP 90 ± 6 95 ± 8a 103 ± 8a,b 87 ± 6c 101 ± 8a 110 ± 8a,b
GFR 108 ± 11 102 ± 12a 104 ± 13a 110 ± 11 100 ± 11a 102 ± 14a
PRA 0.52 ± 0.36 0.28 ± 0.17a 0.18 ± 0.14a,b 0.48 ± 0.31 0.18 ± 0.16a 0.11 ± 0.11a,b
Aldosterone 0.57 ± 0.26 1.10 ± 0.33a 1.41 ± 0.43a,b 0.32 ± 0.14c 1.27 ± 0.38a 1.83 ± 0.54a,b
High-salt
MAP 89 ± 6 97 ± 7a 107 ± 7a,b 89 ± 6 103 ± 8a 114 ± 8a,b
GFR 120 ± 13d 107 ± 11a 109 ± 9a 120 ± 14 105 ± 9a 108 ± 11a,b
PRA 0.19 ± 0.11d 0.11 ± 0.08a 0.08 ± 0.01a 0.20 ± 0.14 0.09 ± 0.11a 0.05 ± 0.08a,b
Aldosterone 0.17 ± 0.09d 0.50 ± 0.24a 0.74 ± 0.28a,b 0.20 ± 0.19 0.63 ± 0.32a 1.05 ± 0.48a,b
Abbreviations are: MAP, mean arterial pressure (mm Hg); GFR (mL/min/1.73 m2); PRA (nmol/L/hour); plasma aldosterone (nmol/L). Data in mean ± SD.
aP < 0.05 during Ang I infusion vs. baseline and washout and during Ang II infusion vs. wash-out; bP < 0.05 angiotensin infusion rate 8 ng/kg/min vs. 4 ng/kg/min;
cP < 0.05 washout vs. baseline; dP < 0.001 high- vs. low-salt diet at baseline.
Table 2. Effect of angiotensin I (Ang I) and angiotensin II (Ang II) infusion on urinary excretion of free cortisol (UFF) and free cortisone (UFE)
during low- and high-salt diet
Ang I Ang I Ang II Ang II
Baseline (4 ng/kg/min) (8 ng/kg/min) Washout (4 ng/kg/min) (8 ng/kg/min)
Low-salt
UFF 0.83 ± 0.48 0.49 ± 0.25a 0.33 ± 0.21a,b 0.73 ± 0.31 0.38 ± 0.14a 0.30 ± 0.22a,b
UFE 1.65 ± 0.61 1.39 ± 0.75 1.21 ± 0.70a 2.35 ± 0.93 1.94 ± 0.75 1.56 ± 0.75a
High-salt
UFF 1.34 ± 1.10c 0.66 ± 0.48a 0.35 ± 0.20a,b 0.96 ± 0.44 0.52 ± 0.30a 0.34 ± 0.31a,b
UFE 2.45 ± 1.11c 1.65 ± 0.84 1.27 ± 0.79a 3.00 ± 1.44 2.08 ± 0.74a 1.81 ± 1.41a,b
Data in mean ± SD and expressed as nmol/mL glomerular filtrate.
aP < 0.05 during Ang I infusion vs. baseline and washout and during Ang II infusion vs. wash-out; bP < 0.05 angiotensin infusion rate 8 ng/kg/min vs. 4 ng/kg/min;
cP < 0.05 high- vs. low-salt diet at baseline.
infusion (data not shown). All subjects were normoten-
sive, while MAP did not change significantly during salt
restriction (Table 1). There was a dose-dependent in-
crease in mean arterial pressure (MAP) during infusion
of Ang I and Ang II infusion at both diets (Table 1). Dur-
ing the low-salt diet, MAP in the washout period follow-
ing Ang I infusion was lower than at baseline (P < 0.05).
After salt restriction, baseline GFR was significantly de-
creased (Table 1). GFR decreased during Ang I and
Ang II administration at both diets (Table 1). Baseline
PRA and plasma aldosterone were increased after salt
restriction (Table 1). Ang I and Ang II infusion resulted
in a dose-dependent decrease in PRA and an increase
in plasma aldosterone, irrespective of sodium intake
(Table 1). During the low-salt diet, plasma aldosterone
was lower in the washout period after Ang I infusion
than at baseline (P < 0.05).
We observed a decrease in the 24-hour excretion of
UFF (25 ± 11 pmol/min/m2 vs. 33 ± 18 pmol/min/m2,
P < 0.05) and of UFE (60 ± 21 pmol/min/m2 vs. 77 ±
33 pmol/min/m2, P < 0.05) after salt restriction, with-
out any change in the ratios of (THF + allo-THF)/THE
(0.99 ± 0.26 vs. 1.01 ± 0.25, NS) and of UFF/UFE (0.42 ±
0.14 vs. 0.41 ± 0.13, NS). At baseline, UFF and UFE,
corrected for GFR, were also lower after salt restric-
tion (Table 2). During Ang I and Ang II infusion,
there was dose-dependent decrease in the excretion rates
of both UFF and UFE, irrespective of sodium intake
(Table 2).
The UFF/UFE ratio at baseline during low- and high-
salt diet was 0.52 ± 0.28 and 0.56 ± 0.45, respectively
(NS). Both Ang I and Ang II infusion resulted in a dose-
dependent decrease of the UFF/UFE ratio at either diet
(Fig. 1). Although the UFF/UFE ratio did not return to
baseline during the washout period after Ang I infusion,
a further decrease in the UFF/UFE ratio was observed at
both diets during infusion of Ang II. The relative Ang I
and Ang II mediated changes in UFF/UFE ratio were not
different between low- and high-salt diets (all P > 0.4).
The urinary (THF + allo-THF)/THE ratio at baseline
during the low- and high-salt diets was 1.25 ± 0.45 and
1.09 ± 0.37, respectively (NS). No changes in this ratio
were observed during either Ang I or Ang II infusion
at both diets (Fig. 2). Correlation analysis did not reveal
significant relationships between changes in UFF/UFE
ratio and changes in MAP, plasma aldosterone, or renin
activity during Ang I and Ang II infusion at either diet
(all P > 0.10). Changes in 24-hour UFF and UFE after
salt restriction did not correlate with changes in PRA and
aldosterone concentration (all P > 0.10).
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Fig. 1. Effect of angiotensin I (Ang I) and angiotensin II (Ang II)
infusion on the urinary free cortisol/free cortisone (UFF/UFE) ratio.
(A) Effect during low-salt diet. (B) Effect during high-salt diet. ∗P <
0.05 vs. baseline; †P < 0.05 vs. washout; ‡P < 0.05 angiotensin infusion
rate 8 ng/kg/min vs. 4 ng/kg/min. Abbreviations are: (4), 4 ng/kg/min;
(8), 8 ng/kg/min.
DISCUSSION
In the current study, we have demonstrated that acute
administration of Ang I and Ang II to healthy male sub-
jects results in a dose-dependent decrease in the urinary
excretion of free cortisol, free cortisone and in the urinary
ratio of free cortisol to free cortisone, irrespective of di-
etary salt intake. Infusion of angiotensin did not affect
the urinary ratio of THF + allo-THF/THE, representing
the overall set point of 11bHSD activity. These findings
strongly suggest that exogenous angiotensin acutely stim-
ulates the activity of 11bHSD type 2 in human kidney.
This is the first study showing acute effects of an-
giotensin infusion on in vivo parameters of 11bHSD ac-
tivity in humans. In a previous study, we found a decrease
in the urinary ratio of THF+allo-THF/THE during treat-
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Fig. 2. Effect of angiotensin I (Ang I) and angiotensin II (Ang II)
infusion on the urinary ratio of tetrahydrocortisol + allotetrahydrocor-
tisol/tetrahydrocortisone (THF + allo-THF/THE). (A) Effect during
low-salt diet. (B) Effect during high-salt diet. Abbreviations are: (4), 4
ng/kg/min; (8), 8 ng/kg/min.
ment with an ACE inhibitor in micro-albuminuric type
1 diabetic patients [18]. Of notice, the UFF/UFE ratio,
which is now generally considered to be a more specific
parameter of renal 11bHSD type 2 activity, was not deter-
mined in that study [15–17]. In another report, we did not
observe an effect of the selective Ang II receptor blocker
losartan given during 4 weeks on either of these 11bHSD
determined ratios in proteinuric patients [19]. Apart from
the timing of 11bHSD assessment during pharmacologic
RAAS inhibition, this lack of effect might have been re-
lated to the relatively low dose of losartan that was admin-
istered in our previous study [19]. Besides these studies
in humans, there are a few in vitro studies and animal ex-
periments focusing on the effect of angiotensin and ACE
inhibition on 11bHSD activity. Riddle and McDaniel [9]
have demonstrated that the activity of 11bHSD was de-
creased after in vitro incubation of rat kidney with Ang
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II, and increased after both in vitro incubation and in vivo
administration to rats of an ACE inhibitor. However, no
distinction between 11bHSD isozymes was made, which
is relevant since rat kidney expresses both 11bHSD type
1 and type 2, whereas there is essentially only expression
of 11bHSD type 2 in human kidney [7, 8]. Moreover,
the effect of in vivo administration of Ang II was not
described in that study. Another in vitro study demon-
strated that 11bHSD type 2 activity in a human colon car-
cinoma cell line was reduced after incubation with Ang
II at supraphysiologic concentrations and increased af-
ter incubation with several ACE inhibitors [10]. These
findings are in contrast to our study, which is probably
explained by differences in target tissues studied and
by the mode of angiotensin administration (i.e., either
through incubation of angiotensin with tissue in vitro or
via systemic infusion of angiotensin in vivo). Of interest,
our results are in agreement with a former in vivo study
showing that Ang II infusion increases 11bHSD dehy-
drogenase activity in rat kidney [11]. In the present study,
endogenous RAAS stimulation by salt restriction did not
affect 11bHSD parameters, which confirms previous ob-
servations [20–22]. Obviously, salt restriction and acute
administration of angiotensin represent two different bi-
ologic stimuli, as also reflected by the difference in corre-
sponding plasma aldosterone levels. Moreover, it should
be noted that sodium restriction not only affects RAAS
activity, but elicits several other responses as well, like
changes in sympathetic activity and in nitric oxide pro-
duction, which in turn could also modulate the activity of
11bHSD type 2 [23–26].
The presently described angiotensin-mediated stimu-
lation of renal 11bHSD type 2 activity will result in a
decreased stimulation of the mineralocorticoid receptor
through an increased inactivation of cortisol. In addition,
the cortisone thus generated might act as an aldosterone
antagonist, as suggested by in vitro binding studies in
which aldosterone was co-incubated with dehydrocorti-
costerone (i.e., the equivalent of cortisone in rodents)
[3, 4]. Taken together, we propose that exogenous an-
giotensin acutely exerts a dual effect on the mineralocor-
ticoid receptor, resulting in an indirect agonistic effect by
increasing aldosterone availability and a direct or indi-
rect antagonistic effect by stimulation of renal 11bHSD
type 2 activity. Conversely, it can be hypothesized that the
natriuretic response to pharmacologic RAAS inhibition
may be limited by the concomitant decrease in Ang II–
mediated inactivation of cortisol and generation of corti-
sone in kidney.
Data on the acute effects of angiotensin infusion
on hypothalamic-pituitary-adrenal (HPA)-axis activity in
humans are limited and suggest either no effect [27, 28]
or a decrease in cortisol secretion [29, 30]. Of note, our
study was primarily designed to examine the effects of an-
giotensin on parameters of 11bHSD activity, rather than
on adrenal glucocorticoid secretion. In view of the dose-
dependent decrease in urinary free cortisol and in free
cortisone excretion during Ang I and II infusion, the re-
covery toward baseline values during the washout period
after Ang I administration, and the fact that these changes
still remained significant after correction for angiotensin-
mediated alterations in GFR, the present data nonethe-
less would raise the possibility that angiotensin infusion
acutely decreases cortisol secretion. Furthermore, there
was an increase in the 24-hour urinary excretion of free
cortisol and free cortisone during the high-salt diet, which
has also been demonstrated in other reports [22, 31].
This is probably explained by a sodium-induced increase
in cortisol elimination [22]. In line with the lowering in
urinary cortisol excretion in response to angiotensin in-
fusion, the possibility arises that salt restriction affects
urinary cortisol excretion by stimulation of endogenous
RAAS activity. However, we were not able to demon-
strate any correlations between changes in PRA or aldos-
terone levels and changes in urinary cortisol excretion.
Thus, it seems that sodium restriction does not affect uri-
nary cortisol excretion via altering endogenous RAAS
activity.
The present data in healthy subjects raise the ques-
tion whether modulation of 11bHSD type 2 activity by
angiotensin could contribute to the pathophysiology of
arterial hypertension. To this end, it will be of interest to
compare the activity of 11bHSD type 2 in patients with
low-renin and high-renin hypertension. Clearly, further
studies are required focusing on the possible interaction
between RAAS and 11bHSD type 2 in hypertension.
Some limitations of the current study need to be
pointed out. We did not perform a sham infusion to cor-
rect for possible circadian changes in 11bHSD activity,
because this would have been too demanding for most
participants. However, it seems very unlikely that the
observed alterations in the UFF/UFE ratios during our
experiment are the result of spontaneous fluctuations, be-
cause these would not explain the clear dose-response
relationship between angiotensin infusion and changes
in the UFF/UFE ratio. Moreover, it has been demon-
strated in healthy normal volunteers that the UFF/UFE
ratio does not decrease from 12 hours to 18 hours, but
might even be increased during the first half of the after-
noon [32]. Finally, it obviously remains unknown whether
the currently described acute changes in 11bHSD activity
are short-lived or will be sustained after more prolonged
exposure to elevated angiotensin levels. However, stud-
ies with prolonged infusion of angiotensins will be very
difficult to perform in humans.
CONCLUSION
Our data suggest that acute administration of an-
giotensin results in stimulation of 11bHSD type 2 in
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human kidney. This observation might imply a novel
direct or indirect mechanism of regulating mineralocorti-
coid receptor activation at the prereceptor level. Future
studies need to direct the question whether the natri-
uretic response to ACE inhibitors and Ang II receptor
blockers will be limited by a simultaneous enhancement
of cortisol-mediated stimulation of the mineralocorticoid
receptor.
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